Brokerages Set Insulet Corporation (NASDAQ:PODD) Target Price at $348.05

Shares of Insulet Corporation (NASDAQ:PODD) have been assigned an average rating of “Moderate Buy” from the twenty-two ratings firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, eighteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $348.0526.

A number of research firms have commented on PODD. The Goldman Sachs Group reduced their price target on Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Citigroup reiterated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Wells Fargo & Company upped their price target on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PODD. Larson Financial Group LLC lifted its stake in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT acquired a new position in Insulet during the 1st quarter worth approximately $26,000. SouthState Corp raised its stake in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the period. Kozak & Associates Inc. acquired a new position in Insulet during the 2nd quarter worth approximately $32,000. Finally, Golden State Wealth Management LLC raised its stake in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares during the period.

Insulet Trading Up 0.7%

Shares of PODD stock opened at $318.59 on Wednesday. The firm has a market capitalization of $22.43 billion, a P/E ratio of 96.84, a P/E/G ratio of 2.64 and a beta of 1.40. Insulet has a twelve month low of $226.50 and a twelve month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock’s fifty day simple moving average is $326.22 and its 200 day simple moving average is $301.98.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet’s quarterly revenue was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts predict that Insulet will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.